Detection Evaluation of a Novel Blood-based DNA Methylation Assay in Early-stage Hepatocellular Carcinoma Patients

UnknownOBSERVATIONAL
Enrollment

4,816

Participants

Timeline

Start Date

November 29, 2021

Primary Completion Date

March 5, 2023

Study Completion Date

April 25, 2023

Conditions
Liver Cancer
Trial Locations (9)

Unknown

Beijing Youan Hospital,Capital Medical University Beijing Institute of Hepatology, Beijing

Xiangya Hospital of Central South University, Changsha

West China School of Medicine/West China Hospital of Sichuan University, Chengdu

Guangzhou eighth People's Hospital ,Guangzhou Medilcal University, Guangzhou

The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou

Nantong Tumor Hospital, Nantong

Ruijin Hospital, Shanghai Jiaotong University School, Shanghai

Wuxi No.5 People's Hospital, Wuxi

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Third Affiliated Hospital, Sun Yat-Sen University

OTHER

collaborator

Guangzhou eighth People's Hospital ,Guangzhou Medilcal University

UNKNOWN

collaborator

The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China

OTHER

collaborator

West China Hospital

OTHER

collaborator

Beijing Youan Hospital,Capital Medical University Beijing Institute of Hepatology

UNKNOWN

collaborator

Ruijin Hospital

OTHER

collaborator

Xiangya Hospital of Central South University

OTHER

collaborator

The First Affiliated Hospital of Zhengzhou University

OTHER

collaborator

Wuxi No.5 People's Hospital

UNKNOWN

collaborator

Peking University First Hospital

OTHER

lead

Genetron Health

INDUSTRY

NCT05343832 - Detection Evaluation of a Novel Blood-based DNA Methylation Assay in Early-stage Hepatocellular Carcinoma Patients | Biotech Hunter | Biotech Hunter